Sandoz Plans to Invest €25 million to expand its Biopharma Technical Development Capabilities in Holzkirchen, Germany

Specifications:

Name:

Sandoz Plans to Invest €25 million to expand its Biopharma Technical Development Capabilities in Holzkirchen, Germany

Location:

Germany

Company:

Sandoz International GmbH

Estimated Cost:

€25 million

Source:

https://www.sandoz.com/

Introduction:

Sandoz plan for investment of approximately EUR 25 million in its site in Holzkirchen, Germany, to expand its Biopharma Technical Development (BioTD) capabilities and complete a state-of-the-art biotech lab by Q4 2023.

Features:

As a result of the investment, Holzkirchen will become one of the primary technical locations for biosimilar development at Sandoz, bringing together state-of-the-art laboratories and analytical expertise at one site. Combined with a major expansion in 2017, this represents a total investment of nearly EUR 100 million in the company’s German headquarters.

Thomas Weigold, Sandoz Country President, Germany, and CEO of Hexal AG: “Our continued investment in Holzkirchen reflects our commitment to expanding our BioTD capabilities and reinforces our dedication to providing high-quality biosimilars to patients worldwide.”

Sandoz has also submitted a request to the Bavarian State Government for research funding to strengthen its development capabilities.

Sandoz is committed to helping millions of patients sustainably and affordably access critical and potentially life-changing biologic medicines across a range of areas including immunology, oncology, supportive care and endocrinology. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.